| Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. | |
| | |
MedLine Citation:
|
PMID: 20507960 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVES: Nearly 30% of renal transplant recipients develops BK viremia, a prerequisite for BK nephropathy. Case reports have evaluated treatment options for BK virus, but no controlled studies have assessed prophylactic therapies. Fluoroquinolone antibiotics were studied for prevention of BK viremia after renal transplantation. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective analysis evaluated adult renal transplant recipients with at least one BK viral load (blood) between 90 and 400 days after transplantation. Six to 12 months of co-trimoxazole was used for Pneumocystis prophylaxis. In sulfa-allergic/-intolerant patients, 6 to 12 months of atovaquone with 1 month of a fluoroquinolone was used. Fluoroquinolones can inhibit BK DNA topoisomerase. The two groups studied were those that received 30 days of levofloxacin or ciprofloxacin after transplantation and those that did not. The primary endpoint was BK viremia rates at 1 year. Of note, of the 160 patients not receiving fluoroquinolone prophylaxis, 40 received a fluoroquinolone for treatment of a bacterial infection within 3 months after transplantation. Subgroup analysis evaluating these 40 patients against the 120 who had no exposure to fluoroquinolones was completed. RESULTS: A 1-month fluoroquinolone course after transplantation was associated with significantly lower rates of BK viremia at 1 year compared with those with no fluoroquinolone. In the subgroup analysis, exposure to fluoroquinolone for treatment of bacterial infections within 3 months after transplantation was associated with significantly lower 1-year rates of BK viremia. CONCLUSIONS: This analysis demonstrates that fluoroquinolones are effective at preventing BK viremia after renal transplantation. |
| | |
Authors:
|
Steven Gabardi; Sushrut S Waikar; Spencer Martin; Keri Roberts; Jie Chen; Lea Borgi; Hussein Sheashaa; Christine Dyer; Sayeed K Malek; Stefan G Tullius; Nidyanandh Vadivel; Monica Grafals; Reza Abdi; Nader Najafian; Edgar Milford; Anil Chandraker |
Publication Detail:
|
Type: Journal Article Date: 2010-05-27 |
Journal Detail:
|
Title: Clinical journal of the American Society of Nephrology : CJASN Volume: 5 ISSN: 1555-905X ISO Abbreviation: Clin J Am Soc Nephrol Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-08 Completed Date: 2010-10-26 Revised Date: 2011-08-01 |
Medline Journal Info:
|
Nlm Unique ID: 101271570 Medline TA: Clin J Am Soc Nephrol Country: United States |
Other Details:
|
Languages: eng Pagination: 1298-304 Citation Subset: IM |
Affiliation:
|
Department of Transplant Surgery, Center for for Clinical Investigation, Brigham and Women's Hospital, and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. sgabardi@partners.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antiviral Agents / administration & dosage* BK Virus / pathogenicity* Boston Female Fluoroquinolones / administration & dosage* Humans Immunosuppressive Agents / adverse effects Kidney Transplantation* / adverse effects Male Middle Aged Polyomavirus Infections / diagnosis, prevention & control*, virology Retrospective Studies Time Factors Treatment Outcome Viral Load Viremia / prevention & control |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Fluoroquinolones; 0/Immunosuppressive Agents |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The ASN in-training examination and the ABIM certifying examination: time for a new testing paradigm...
Next Document: Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after r...